Phase 2/3 Data for High-Dose Aflibercept for DME

David M. Brown, MD

Show Description +

David M. Brown, MD, discusses 48-week data for 8 mg aflibercept in the treatment of diabetic macular edema, noting that the vast majority of study patients maintaned 12- or 16-week dosing.

Posted: 10/10/2022

Keywords:

aflibercept

•

Diabetic macular edema, DME

•

retina-meeting-recap

•

Clinical Trials

•

Retina Subspecialty Day

Up Next

Name: Phase 2/3 Data for High-Dose Aflibercept for DME
Uploaded: 2022-10-10T20:32:00+00:00
Description: David M. Brown, MD, discusses 48-week data for 8 mg aflibercept in the treatment of diabetic macular edema, noting that the vast majority of study patients maintaned 12- or 16-week dosing.

Protocol AC Guides DME Treatment Approaches

Chirag D. Jhaveri, MD

How to Deploy Home OCT

Nancy M. Holekamp, MD

Phase 2 STORM Trial Shows Positive Outcomes

Francis Price, MD

Documenting for Patient Care

Bradley Henriksen, MD

Mask-Associated Dry Eye Syndrome

New Devices in Glaucoma

Oluwatosin Smith, MD, and Qi Cui, MD

Optics 101: Matching Optics to Available Technology

Julie Schallhorn, MD

One-Year Visual Outcomes Following Monocular Implantation With a Small-Aperture IOL

Mark Blecher, MD

The FDA Perspective: The Link Between Medical Devices and Patients

Michelle E. Tarver, MD

The Six Traits of an Inclusive Practice Leader

Rupa Wong, MD

$A Refractive Surgery Journey and Lessons Learned$

A Refractive Surgery Journey and Lessons Learned

Sheraz M. Daya, MD, FACP, FACS, FRCS(Ed), FRCOphth

A Look at a New Shape-Changing IOL

Eric D. Donnenfeld, MD

IOL Calculations: The Internet Way

Oliver Findl, MD, MBA

Corneal Ulceration in Patients With Ocular Graft-Versus-Host Disease

Rahul Tonk, MD; Paula Sepulveda, MD

Evaluating the Efficacy of a ROCK Inhibitor for the Treatment of Corneal Edema

Himani Goyal, MD; Adanna Udeh, MD

Dr. Avery’s AAO 2022 Can’t-Miss Retina Sessions

Robert L. Avery, MD

Ocular Inflammation in Retinal Gene Therapies

Glenn C. Yiu, MD, PhD

The State of Macular Hole Surgery

Sophie J. Bakri, MD

A Look at Private Equity in Retina

John T. Thompson, MD

Avoid PDR Complications With Early Vitrectomy

Maria H. Berrocal, MD

GA Update: Phase 3 Data for Pegcetacoplan

Charles C. Wykoff, MD, PhD

Back to All Videos

Phase 2/3 Data for High-Dose Aflibercept for DME

David M. Brown, MD

David M. Brown, MD, discusses 48-week data for 8 mg aflibercept in the treatment of diabetic macular edema, noting that the vast majority of study patients maintaned 12- or 16-week dosing.

Posted: 10/10/2022

Keywords:

aflibercept

•

Diabetic macular edema, DME

•

retina-meeting-recap

•

Clinical Trials

•

Retina Subspecialty Day

Please log in to leave a comment.

Meeting Coverage:

American Academy of Ophthalmology

Phase 2/3 Data for High-Dose Aflibercept for DME

Up Next

Phase 2/3 Data for High-Dose Aflibercept for DME

More From AAO: 2022 Coverage